Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
复制标题
AS 与 SOX 方案作为胃癌腹膜转移患者一线化疗的疗效：一项真实世界研究
DOI：
10.1186/s12876-022-02369-9
复制
发表时间：
2022-06-14
影响因子：
2.4
通讯作者：
Cui, Yuehong
中科院分区：
文献类型：
--
作者：
Zhang, Lingyun;Zhang, Jiayu;Wang, Yan;Li, Wei;Yu, Shan;Li, Qian;Yu, Yiyi;Liu, Tianshu;Cui, Yuehong
比较AS（白蛋白结合紫杉醇和S-1）与SOX（S-1和奥沙利铂）一线全身化疗方案治疗中国胃癌腹膜转移患者的预后。这是一项在接受AS或SOX方案作为一线化疗的胃癌腹膜转移患者中进行的真实世界研究。采用倾向评分匹配法（PSM）进行配对。主要和次要终点为总生存期（OS）和无进展生存期（PFS）。经PSM分析后，共纳入108例胃癌腹膜转移患者。PSM分析后，AS和SOX方案在性别、年龄、腹水、治疗周期、胃癌切除、接受检查点抑制剂和HER-2表达方面无显著差异。接受AS方案的患者的中位OS（14.13 vs. 11.17个月，p = 0.0356）和中位PFS（10.30 vs. 6.70个月，p = 0.0003）均长于接受SOX方案作为一线全身化疗的患者。亚组分析中，Lauren弥漫型患者AS方案的中位OS和中位PFS均长于SOX方案。两组毒副反应发生率无显著性差异。结果证实AS方案对胃癌腹膜转移的疗效优于SOX方案，尤其对Lauren弥漫型胃癌腹膜转移的疗效更佳。
To compare the prognosis of first-line systemic chemotherapy of AS (Albumin-bound paclitaxel and S-1) versus SOX (S-1 and oxaliplatin) regimen in Chinese gastric cancer patients with peritoneal metastasis. This was a real-world study of gastric cancer patients with peritoneal metastasis who have been treated with AS or SOX regimen as first-line chemotherapy. Patients were matched by the method of propensity score matching (PSM). The primary and secondary endpoints were overall survival (OS) and progress-free survival (PFS). A total of 108 gastric cancer patients with peritoneal metastasis were enrolled after PSM analysis. There was no significant difference between AS and SOX regimen based on gender, age, ascites, treatment cycles, gastric cancer resection, received checkpoint inhibitors, and HER-2 expression after PSM analysis. The median OS (14.13 vs. 11.17 months, p = 0.0356) and median PFS (10.30 vs. 6.70 months, p = 0.0003) of patients who received AS regimen were longer than those treated by SOX regimen as first-line systemic chemotherapy. In sub-group analysis, the median OS and median PFS were longer for patients in AS regimen than SOX regimen in Lauren diffuse type. The occurrence of toxicity between the two groups was shown no significant difference. The results verified that AS regimen was more effective than SOX chemotherapy in gastric cancer patients with peritoneal metastasis, especially in Lauren diffuse type.
登录
查看更多内容
影响因子：
11.5
作者：
Desai, N;Trieu, V;Soon-Shiong, P
通讯作者：
Soon-Shiong, P
影响因子：
3.8
作者：
Hirata, Kenro;Hamamoto, Yasuo;Muro, Kei
通讯作者：
Muro, Kei
影响因子：
4.3
作者：
Berlth, Felix;Bollschweiler, Elfriede;Moenig, Stefan
通讯作者：
Moenig, Stefan
DOI：
10.1111/apm.1965.64.1.31
发表时间：
1965-01-01
期刊：
ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA
影响因子：
--
作者：
LAUREN, P
通讯作者：
LAUREN, P
一线Nivolumab加化学疗法与化学疗法仅用于晚期胃，胃食管结和食管腺癌（Checkmate 649）：一项随机，开放标签，第3阶段试验。
DOI：
10.1016/s0140-6736(21)00797-2
发表时间：
2021-07-03
期刊：
Lancet (London, England)
影响因子：
--
作者：
Janjigian YY;Shitara K;Moehler M;Garrido M;Salman P;Shen L;Wyrwicz L;Yamaguchi K;Skoczylas T;Campos Bragagnoli A;Liu T;Schenker M;Yanez P;Tehfe M;Kowalyszyn R;Karamouzis MV;Bruges R;Zander T;Pazo-Cid R;Hitre E;Feeney K;Cleary JM;Poulart V;Cullen D;Lei M;Xiao H;Kondo K;Li M;Ajani JA
通讯作者：
Ajani JA